🎉Another historic moment🎉 We’re proud to be the FIRST IN TEXAS to utilize the new FDA-approved Edwards' EVOQUE Tricuspid Valve Replacement System! After playing a pivotal role in the TRISCEND II Clinical Trial for this device, we’re excited to advance research and patient care.

In the TRISCEND II pivotal trial, AF was found in 95% of patients. Thus, evaluation for transcatheter tricuspid valve replacement provides an important opportunity to reassess the management of AF. #Epeeps, join the conversation on EPLD's AF Topic Center! https://t.co/DhuadweL36

Simultaneous publication during #ESCCongress Clinical outcomes of transcatheter tricuspid valve replacement stratified by baseline tricuspid regurgitation severity from the TRISCEND II Trial - https://t.co/kMDlORoG4k #EHJ

Transcatheter Valve Replacement in Severe Tricuspid Regurgitation: @NEJM 🥸 TRISCEND II Trial - #TCT2024 😱 Summary 👇👇👇

TRISCEND II subanalysis showed greater benefit of TTVR in massive/torrential TR, suggesting this may be the target population ( https://t.co/OLkOdJCnH4). In our paper just published, massive/torrential TR did not reduce TTVI eligibility vs severe TR ( https://t.co/s8wVRaNOH3)

🤩 #LBCS advances in VHD @ #ESCcongress TRISCEND II RCT subanalysis by baseline TR 📌primary EP of TTVR vs OMT @ 1 yr ✅ 📌greater symptomatic/functional benefit in 4+/5+ TR (attenuated treatment effect in 3+?) 📌reduced HF @ 18 Mo in 4+/5+ TR @escardio

Simultaneous publication during #ESCCongress Clinical outcomes of transcatheter tricuspid valve replacement stratified by baseline tricuspid regurgitation severity from the TRISCEND II Trial. https://t.co/Il6BKWeEDv #TRISCENDTrial #HeartValveDisease @EScardio @ESC_Journals

Echocardiography findings from #TRISCEND II presented at #NYValves2025 @crfheart

🔴Original Article: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation (TRISCEND II trial) https://t.co/w8AOmFXqj1 🔴Editorial: Early-Stage Results with Transcatheter Tricuspid-Valve Replacement https://t.co/CydHCkM0Gc #Cardiology

🥇📷Top late-breaking trials presented today at #PCRLV 2⃣ TRISCEND II trial: 🧐 Evoque x medical therapy 👉 400 patients (2:1 randomization) 👉 1y Composite endpoint (death, RV assist device/ heart transplantation, TV intervention, HF hospitalization,

Our editorial in EHJ commenting on the 12-month TRISCEND results in TR with the Evoque valve wherein we discuss our insights across the major experiences with TriClip and TTVR. https://t.co/7khtdqe755

Get ready to witness groundbreaking data @ #TCT2024! In collaboration with @JAMA_current this session features: ✨TRISCEND II ✨ACURATE IDE ✨FAVOR III Europe ✨FLASH @arnoldgehrke @SusheelKodaliMD @MReardon19 @NielsRHolm @wfearonmd @npfam1 @LindaGillamMD @jgranadacrf @mmamas1973

Special Episode of #EaglesEyeView: #TCT2023 Preview Dr. @keaglemd shares some of the trials being presented during TCT 2023, including TRISCEND II; 4 Year Outcomes from the EVOLUT Low Risk Trial; and more! Listen to the episode here: https://t.co/fj54fyyFFu #ACCEd

V interesting data from @FabienPraz from TRISCEND 1 study evaluating Evoque transcatheter tricuspid valve replacement system Note ⬇️⬇️TR *was* associated with ⬆️⬆️ 6MWD, unlike #TRILUMINATE Different patient populations? Better TR reduction? Deserves scrutiny! @drjohnm

#TCT2023 Following 12 Late Breaking RCT to be presented at 2023 TCT PARTNER 3 Low-Risk EVOLUT Low Risk WATCH TAVR ALIGN-AR LIFE-BTK AGENT IDE PICSO-AMI-I T-PASS TRISCEND II TRILUMINATE VIVA CLASPIID @crfheart @TCTConference

Bryan Zweig, MD discusses how data from the CLASP IID and TRISCEND II trials have influenced his referral management for patients with tricuspid regurgitation. He highlights the positive step forward for patients with this effective approach. Stream the full session here –

Presenting results from TRISCEND II at #TCT2024, Suzanne V. Arnold (@arnoldgehrke), MD, provides insight on quality-of-life improvements for patients with severe tricuspid regurgitation who undergo transcatheter valve replacement. @TCTMD

Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Read more in #EHJ #tricuspidvalve #CardioTwitter https://t.co/wB4HUEqp5a

Presenting results from TRISCEND II at #TCT2024, Suzanne V. Arnold (@arnoldgehrke), MD, provides insight on quality-of-life improvements for patients with severe tricuspid regurgitation who undergo transcatheter valve replacement. @TCTMD